Immune deficiency in HIV-1 infection: novel therapeutic approaches targeting innate and adaptive responses

References

• De Milito A. B-lymphocyte dysfunctions in HIV infection. Curr. HIV Res. 2, 11–21 (2004).
   PubMed Web of Science ®Google Scholar
• De Milito A, Nilsson A, Titanji K et al. Mechanisms of hypergammaglobulinemia and impaired antigen-specific humoral immunity in HIV-1 infection. Blood 103(6), 2180–2186 (2004).
   PubMed Web of Science ®Google Scholar
• Martinez-Maza O, Breen EC. B-cell activation and lymphoma in patients with HIV. Curr. Opin.Oncol. 14, 528–532 (2002).
   PubMedGoogle Scholar
• De Milito A, Morch C, Sonnerborg A, Chiodi F. Loss of memory (CD27) B-lymphocytes in HIV-1 infection. AIDS 15, 957–964 (2001).
   PubMed Web of Science ®Google Scholar
• Moir S, Malaspina A, Li Y et al. B-cells of HIV-1 infected patients bind virions through CD21-complement interactions and transmit infectious virus to activated T-cells. J. Exp. Med. 192, 637–646 (2000).
   PubMed Web of Science ®Google Scholar
• Moir S, Malaspina A, Pickeral OK et al. Decreased survival of B-cells of HIV-viremic patients mediated by altered expression of receptors of the TNF- superfamily. J. Exp. Med. 200(5), 587–600 (2004).
   Web of Science ®Google Scholar
• Kroon FP, van Dissel JT, Ravensbergen E, Nibering PH, van Furth R. Antibodies against pneumococcal polysaccharides after vaccination in HIV- infected individuals: 5-year follow-up of antibody concentrations. Vaccine 18, 524–530 (1999).
   PubMedGoogle Scholar
• Malaspina A, Moir S, Shyamasundaran K et al. Deleterious effect of HIV-1 plasma viremia on B-cell costimulatory function. J. Immunol. 170, 5965–5972 (2003).
   PubMed Web of Science ®Google Scholar
• Borrow P, Lewicki H, Wei X et al. Antiviral pressure exerted by HIV -1-specific cytotoxic T-lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nature Med. 3, 205–211 (1997).
   PubMed Web of Science ®Google Scholar
• Schmitz JE, Kuroda MJ, Santra S et al. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science 283, 857–860 (1999).
   PubMed Web of Science ®Google Scholar
• McMichael AJ, Rowland-Jones SL. Cellular immune responses to HIV. Nature 410, 980–986 (2001).
   PubMed Web of Science ®Google Scholar
• Lieberman J, Shankar P, Manjunath N, Andersson J. Dressed to kill? A review of why antiviral CD8 T-lymphocytes fail to prevent progressive immunodeficiency in HIV-1 infection. Blood 98, 1667–1677 (2001).
   PubMed Web of Science ®Google Scholar
• Van Baarle D, Kostense S, van Oers MH., Hamann D, Miedema F. Failing immune control as a result of impaired CD8+ T-cell maturation: CD27 might provide a clue. Trends. Immunol. 23(12), 586–591 (2002).
   PubMed Web of Science ®Google Scholar
• Lichterfeld M, Kaufmann DE, Yu XG et al. Loss of HIV-1-specific CD8+ T-cell proliferation after acute HIV-1 infection and restoration by vaccine-induced HIV-1-specific CD4+ T-cells. J. Exp. Med. 200(6), 701–712 (2004).
   PubMed Web of Science ®Google Scholar
• Tomiyama H, Fujiwara M, Oka S, Takiguchi M. Epitope-dependent effect of nef-mediated HLA class I downregulation on ability of HIV-1-specific CTLs to suppress HIV-1 replication. J. Immunol. 174, 36–40 (2005).
   PubMedGoogle Scholar
• Cao J, McNevin J, Malkotra U, McElrath J. Evolution of CD8+ T-cell immunity and viral escape following acute HIV-1 infection. J. Immunol. 171, 3837–3846 (2003).
   PubMed Web of Science ®Google Scholar
• Zhang D, Shankar P, Xu Z et al. Most antiviral CD8 T-cells during chronic viral infection do not express high levels of perforin and are not directly cytotoxic. Blood 101(1), 226–235 (2003).
   PubMedGoogle Scholar
• Ueno T, Tomiyama H, Fujiwara M, Oka S, Takiguchi M. Functionally impaired HIV-specific CD8 T-cells show high affinity TCR-ligand interactions. J. Immunol. 173, 5451–5457 (2004).
   PubMedGoogle Scholar
• Shacklett BL, Cox CA, Quigley MF et al. Abundant expression of granzyme A, but not perforin, in granules of CD8+ T-cells in GALT: implications for immune control of HIV-1 infection. J. Immunol. 173, 641–648 (2004).
   PubMedGoogle Scholar
• Petrovas C, Mueller YM, Dimitriou ID et al. HIV-specific CD8 T-cells exhibit markedly reduced levels of Bcl-2 and Bcl-xL. J. Immunol. 172, 4444–4453 (2004).
   PubMedGoogle Scholar
• Trimble LA, Lieberman J. Circulating CD8 T-lymphocytes in human immunodeficiency virus-infected individuals have impaired function and downmodulate CD3 zeta, the signaling chain of T-cell receptor complex. Blood 91, 585–594 (1998).
   PubMedGoogle Scholar
• Paiardini M, Cervasi B, Albrecht H et al. Loss of CD127 expression defines an expansion of effector CD8+ T-cells in HIV-infected individuals. J. Immunol. 174, 2900–2909 (2005).
   PubMed Web of Science ®Google Scholar
• Sullivan YB, Landay AL, Zack JA, Kitchen SG, Al-Harthi L. Upregulation of CD4 on CD8+ T-cells: CD4dimCD8bright T-cells constitute an activated phenotype of CD8+ T-cells. Immunology 103, 270–280 (2001).
   PubMed Web of Science ®Google Scholar
• Zloza A, Sullivan YB, Connick E, Landay AL, Al-Harthi L. CD8+ T-cells that express CD4 on their surface (CD4dimCD8brignt T-cells) recognize an antigen-specific target, are detected in vivo, and can be productively infected by T-tropic HIV. Blood 102(6), 2156–2164 (2003).
   PubMedGoogle Scholar
• Flamand L, Crowley RW, Lusso P, Colombini-Hatch S, Margolis DM, Gallo RC. Activationof CD8+ T-lymphocytes through the T-cell receptor turns on CD4 gene expression: implications for pathogenesis. Proc. Natl Acad. Sci. USA 95, 3111–3116 (1998).
   PubMed Web of Science ®Google Scholar
• Semenzato G, Agostini C, Ometto L et al. CD8+ T-lymphocytes in the lung of acquired immunodeficiency syndrome patients harbor human immunodeficiency virus Type 1. Blood 85, 2308–2314 (1995).
   PubMedGoogle Scholar
• Douek DC, Picker LJ, Koup RA. T-cell dynamics in HIV-1 infection. Ann. Rev. Immunol. 21, 265–304 (2003).
   PubMed Web of Science ®Google Scholar
• Veazey RS, DeMaria M, Chalifoux LV et al. Gastrointestinal tract as a major site of CD4+ T-cell deplection and viral replication in SIV infection. Science 280, 427–431 (1998).
   PubMed Web of Science ®Google Scholar
• Mehandru S, Poles MA, Tenner-Racz K et al. Primary HIV-1 infection is associated with preferential depletion of CD4+ T-lymphocytes from effector sites in the gastrointestinal tract. J. Exp. Med. 200, 761–770 (2004).
   PubMed Web of Science ®Google Scholar
• Brenchley JM, Schacker TW, Ruff LE et al. CD4+ T-cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J. Exp. Med. 200, 749–759 (2004).
   PubMed Web of Science ®Google Scholar
• Qingsheng L, Duan L, Estes JD et al. Peak SIV replication in resting memory CD4+ T-cells depletes gut lamina propria CD4+ T-cells. Nature 434, 1148–1152 (2005).
   PubMedGoogle Scholar
• Mattapallil JJ, Douek DC, Hill B, Nishimura Y, Martin M, Roederer M. Massive infection and loss of memory CD4+ T-cells in multiple tissues during acute SIV infection. Nature 434, 1093–1097 (2005).
   PubMed Web of Science ®Google Scholar
• Gea-Banacloche JC, Migueles SA, Martino L et al. Maintenance of large numbers of virus-specific CD8+ T-cells in HIV-infected progressors and long-term non-progressors. J. Immunol. 164, 1082–1092 (2000).
   Google Scholar
• Betts MR, Ambrozak DA, Douek DC et al. Analysis of total human immunodeficiency virus (HIV)-specific CD4 and CD8 T-cell responses: relationship to viral load in untreated HIV infection. J. Virol. 75, 11983–11991 (2001).
   PubMed Web of Science ®Google Scholar
• McNeil AC, Shupert WL, Iyasere CA et al. High-level HIV-1 viremia suppresses viral antigen-specific CD4+ T-cell proliferation. Proc. Natl Acad. Sci. USA 98, 13878–13883 (2001).
   PubMed Web of Science ®Google Scholar
• Grossman Z, Feinberg MB, Paul WE. Multiple modes of cellular activation and virus transmission in HIV infection: a role for chronically and latently infected cells in sustaining viral replication. Proc. Natl Acad. Sci. USA 95, 6314–6319 (1998).
   PubMedGoogle Scholar
• Douek DC, Brenchley JM, Betts MR et al. HIV preferentially infects HIV- specific CD4+ T-cells. Nature 417, 95–98 (2002).
   PubMed Web of Science ®Google Scholar
• Hellerstein MK, Hoh RA, Hanley MB et al. Subpopulations of long-lived and short-lived T-cells in advanced HIV-1 infection. J. Clin. Invest. 112(6), 956–966 (2003).
   PubMed Web of Science ®Google Scholar
• Yue FY, Kovacs CM, Dimayuga RC, Parks P, Ostrowski MA. HIV-1-specific memory CD4+ T-cells are phenotypically less mature than cytomegalovirus-specific memory CD4+ T-cells. J. Immunol. 172, 2476–2486 (2004).
   PubMedGoogle Scholar
• Palmer BE, Boritz E, Wilson CC. Effects of sustained HIV-1 plasma viremia on HIV-1 gag-specific CD4+ T-cell maturation and function. J. Immunol. 172, 3337–3347 (2004).
   PubMedGoogle Scholar
• Yue FY, Kovacs CM, Dimayuga RC et al. Preferential apoptosis of HIV-1-specific CD4+ T-cells. J. Immunol. 174, 2196–2204 (2005).
   PubMed Web of Science ®Google Scholar
• Holm GH, Gabuzda D. Distinct mechanisms of CD4+ and CD8+ T-cell activation and bystander apoptosis induced by human immunodeficiency virus Type 1 virions. J. Virol. 79(10), 6299–6311 (2005).
   PubMedGoogle Scholar
• Douek DC. Disrupting T-cell homeostasis: how HIV-1 infection causes disease. AIDS Rev. 5(3), 172–177 (2003).
   Google Scholar
• Paiardini M, Cervasi B, Dunham R, Sumpter B, Radziewicz H, Silvestri G. Cell-cycle dysregulation in the immunopathogenesis of AIDS. Immunol. Res. 29(1–3), 253–268 (2004).
   Google Scholar
• Alfano M, Poli G. The cytokine network in HIV infection. Curr. Mol. Med. 2(8), 677–689 (2002).
   PubMedGoogle Scholar
• Ostrowski SR, Gerstoft J, Pedersen BK, Ullum H. Impaired production of cytokines is an independent predictor of mortality in HIV-1-infected patients. AIDS 17, 521–530 (2003).
   PubMedGoogle Scholar
• Ng WF, Duggan PJ, Ponchel F et al. Human CD4+CD25+ cells; a naturally occurring population of regulatory T-cells. Blood 98(9), 2736–2744 (2001).
   PubMed Web of Science ®Google Scholar
• Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T-cells. Nature Immunol. 4(4), 330–336 (2003).
   PubMed Web of Science ®Google Scholar
• Fontenot JD, Rasmussen JP, Williams LM, Dooley JL, Farr AG, Rudensky AY. Regulatory T-cell lineage specification by the forkhead transcription factor foxp3. Immunity 22(3), 329–341 (2005).
   PubMed Web of Science ®Google Scholar
• Fehervari Z, Sakaguchi S. CD4+ Tregs and immune control. J. Clin. Invest. 114(9), 1209–1217 (2004).
   PubMed Web of Science ®Google Scholar
• Robinson DS, Larche M, Durham SR. Tregs and allergic disease. J. Clin. Invest. 114 (10), 1389–1397 (2004).
   PubMed Web of Science ®Google Scholar
• Rouse BT, Suvas S. Regulatory cells and infectious agents: detentes cordiale and contraire. J. Immunol. 173, 2211–2215 (2004).
   PubMed Web of Science ®Google Scholar
• Bettelli E, Dastrange M, Oukka M. Foxp3 interacts with nuclear factor of activated T-cells and NF-κB to repress cytokine gene expression and effector functions of T-helper cells. Proc. Natl Acad. Sci. USA 102, 5138–5143 (2005).
   PubMed Web of Science ®Google Scholar
• Oldenhove G, de Heusch M, Urbain-Vansanten G et al. CD4+CD25+ regulatory T-cells control T-helper cell Type 1 responses to foreign antigens induced by mature dendritic cells in vivo. J. Exp. Med. 198(2), 259–266 (2003).
   PubMed Web of Science ®Google Scholar
• Piccirillo CA, Shevach E. Control of CD8+ T-cell activation by CD4+CD25+ immunoregulatory cells. J. Immunol. 167, 1137–1140 (2001).
   PubMed Web of Science ®Google Scholar
• Taams LS, van Amelsfort JMR, Tiemessen MM et al. Modulation of monocyte/macrophage function by human CD4+CD25+ regulatory T-cells. Human. Immunol. 66, 222–230 (2005).
   PubMed Web of Science ®Google Scholar
• Hasenkrug KJ. CD4+ regulatory T-cells in chronic viral infection. Novartis Found. Symp. 252, 194–199 (2003).
   PubMedGoogle Scholar
• Boyer O, Saadoun D, Abriol J et al. CD4+CD25+ regulatory T-cell deficiency in patients with hepatitis C-mixed cryoglobulinemia vasculitis. Blood 103(9), 3428–3430 (2004).
   PubMed Web of Science ®Google Scholar
• Yamano Y, Takenouchi N, Li H-C et al. Virus-induced dysfunction of CD4+CD25+ T-cells in patients with HTLV-I-associated neuroimmunological disease. J. Clin. Invest. 115, 1361–1368 (2005).
   PubMedGoogle Scholar
• Suvas S, Kumaraguru U, Pack CD, Lee S, Rouse BT. CD4+CD25+ T-cells regulate virus-specific primary and memory CD8 T cell responses. J. Exp. Med. 198(6), 889–901 (2003).
   PubMed Web of Science ®Google Scholar
• Dittmer U, He H, Messer RJ et al. Functional impairment of CD8+ T-cells by regulatory T-cells during persistent retroviral infection. Immunity 20, 293–303 (2004).
   PubMed Web of Science ®Google Scholar
• Vahlenkamp TW, Tompkins MB, Tompkins WAF. Feline immunodeficiency virus infection phenotypically and functionally activates immunosuppressive CD4+CD25+ T regulatory cells. J. Immunol. 172, 4752–4761 (2004).
   PubMed Web of Science ®Google Scholar
• Beilharz MW, Sammels LM, Paun A et al. Timed ablation of regulatory CD4+ T-cells can prevent murine AIDS progression. J. Immunol. 172, 4917–4925 (2004).
   PubMedGoogle Scholar
• Oswald-Richter K, Grill SM, Shariat N et al. HIV infection of naturally occurring and genetically reprogrammed human regulatory T-cells. PLoS. Biol. 2(7), E198 (2004).
   PubMedGoogle Scholar
• Eggena MP, Barugahare B, Jones N et al. Depletion of regulatory T-cells in HIV infection is associated with immune activation. J. Immunol. 174, 4407–4414 (2005).
   PubMed Web of Science ®Google Scholar
• Andersson J, Boasso A, Nilsson J et al. The prevalence of regulatory T-cells in lymphoid tissue is correlated with viral load in HIV- infected patients. J. Immunol 174, 3143–3147 (2005).
   PubMed Web of Science ®Google Scholar
• Aandahl EM, Michaelsson J, Moretto WJ, Hecht FM, Nixon DF. Human CD4+ CD25+ regulatory T-cells control T-cell responses to human immunodeficiency virus and cytomegalovirus antigens. J. Virol. 78(5), 2454–2459 (2004).
   PubMed Web of Science ®Google Scholar
• Weiss L, Donkova-Petrini V, Caccavelli L, Balbo M, Carbonneil C, Levy Y. Human immunodeficiency virus-driven expansion of CD4+CD25+ regulatory T-cells, which suppress HIV-specific CD4 T-cell responses in HIV-infected patients. Blood 104(10), 3249–3256 (2004).
   PubMedGoogle Scholar
• Kinter AL, Hennessey M, Bell A et al. CD25+CD4+ regulatory T-cells from peripheral Blood of asymptomatic HIV-infected individuals regulate CD4+ and CD8+ HIV-specific T-cell immune responses in vitro and are associated with favorable clinical markers of disease status. J. Exp. Med. 200(3), 331–343 (2004).
   PubMed Web of Science ®Google Scholar
• Kornfeld C. Ploquin MJ-Y, Pandrea I et al. Anti-inflammatory profiles during primary SIV infection in African green monkeys are associated with protection against AIDS. J. Clin. Invest. 115(4), 1082–1091 (2005).
   PubMed Web of Science ®Google Scholar
• Basset C, Holton J, O’Mahony R, Roitt I. Innate immunity and pathogen-host interaction. Vaccine 21(Suppl. 2), 12–23 (2003).
   PubMed Web of Science ®Google Scholar
• Alfano M, Poli G. Role of cytokines and chemokines in the regulation of innate immunity and HIV infection. Mol. Immunol. 42, 161–182 (2005).
   PubMedGoogle Scholar
• Ma G, Greenwell-Wild T, Lei K et al. Secretory leukocyte protease inhibitor binds to annexin II, a co-factor for macrophage HIV-1 infection. J. Exp. Med. 200(10), 1337–1346 (2004).
   PubMed Web of Science ®Google Scholar
• McNeely TB, Shugars DC, Rosendahl M, Tucker C, Eisenberg SP, Wahl SM. Inhibition of human immunodeficiency virus Type 1 infectivity by secretory leukocyte protease inhibitor occurs prior to viral reverse transcription. Blood 90(3), 1141–1149 (1997).
   PubMed Web of Science ®Google Scholar
• Levy JA. The search for the CD8+ cell antiHIV factor (CAF). Trends Immunol. 24(12), 628–632 (2003).
   PubMed Web of Science ®Google Scholar
• Mackewicz CE, Yuan J, Tran P et al. α-defensins can have antiHIV activity but are not CD8 cell antiHIV factors. AIDS 17, F23–F32 (2003).
   PubMed Web of Science ®Google Scholar
• Chang TL, Vargas J, DelPortillo A, Klotman ME. Dual role of α-defensin-1 in antiHIV-1 innate immunity. J. Clin. Invest. 115(3), 765–773 (2005).
   PubMed Web of Science ®Google Scholar
• Quinones-Mateu ME, Lederman MM, Feng Z et al. Human epithetial β-defensis 2 and 3 inhibit HIV-1 replication. AIDS 17, F39–F48 (2003).
   PubMed Web of Science ®Google Scholar
• Chiu Y-L, Soros VB, Kreisberg JF, Stopak K, YonemotoW, Greene WC. Cellular APOBEC3G restricts HIV-1 infection in resting CD4+ T-cells. Nature 435(7038), 108–115 (2005).
   PubMed Web of Science ®Google Scholar
• Zheng Y-H, Lovsin N, Peterlin BM. Newly identified host factors modulate HIV replication. Immunol. Lett. 97, 225–234 (2005).
   PubMedGoogle Scholar
• Stremlau M, Owens CM, Perron MJ, Kiessling M, Autissier P, Sodroski J. The cytoplasmic body component TRIM5 restricts HIV-1 infection in old world monkeys. Nature 427, 848–853 (2004).
   PubMed Web of Science ®Google Scholar
• Ganesh L, Burstein E, Guha-Niyogi A et al. The gene product MurR1 restricts HIV-1 replication in resting CD4+ lymphocytes. Nature 426, 853–857 (2003).
   PubMed Web of Science ®Google Scholar
• Carlson KA, Leisman G, Limoges J et al. Molecular characterization of a putative antiretroviral transcriptional factor, OTK18. J. Immunol. 172, 381–391 (2004).
   PubMedGoogle Scholar
• Stoiber H, Kacani L, Speth C, Wurzner R, Dierich MP. The supportive role of complement in HIV pathogenesis. Immunol. Rev. 180, 168–176 (2001).
   PubMed Web of Science ®Google Scholar
• Stoiber H, Speth C, Dierich MP. Role of complement in the control of HIV dynamics and pathogenesis. Vaccine 21(Suppl. 2), 77–82 (2003).
   Google Scholar
• Horakova E, Gasser O, Sadallah S et al. Complement mediates the binding of HIV to erythrocytes. J. Immunol. 173, 4236–4241 (2004).
   PubMedGoogle Scholar
• Banki Z, Kacani L, Rusert P et al. Complement dependent trapping of infectious HIV in human lymphoid tissues. AIDS 19(5), 481–486 (2005).
   PubMedGoogle Scholar
• Banki Z, Stoiber H, Dierich MP. HIV and human complement: inefficient virolysis and effective adherence. Immunol. Lett. 97, 209–214 (2005).
   PubMedGoogle Scholar
• Ji X, Gewurz H, Spear GT. Mannose binding lectin (MBL) and HIV. Mol. Immunol. 42, 145–152 (2005).
   PubMed Web of Science ®Google Scholar
• Peters-Golden M, Canetti C, Mancuso P, Coffey MJ. Leukotrienes: underappreciated mediators of innate immune responses. J. Immunol. 173, 589–594 (2004).
   Google Scholar
• Chan WL, Pejnovic N, Liew TV, Lee CA, Groves R, Hamilton H. NKT cell subsets in infection and inflammation. Immunol. Lett. 85, 159–163 (2003).
   PubMedGoogle Scholar
• Motsinger A, Haas DW, Stanic AK, Van Kaer L, Joyce S, Unutmaz D. CD1d-restricted human natural killer T-cells are highly susceptible to human immunodeficiency virus 1 infection. J. Exp. Med. 195(7), 869–879 (2002).
   PubMed Web of Science ®Google Scholar
• van der Vliet, von Blomberg BM, Hazenberg MD et al. Selective decrease in circulating V-α 24+V−β 11+NKT cells during HIV Type 1 infection. J. Immunol. 168(3), 1490–1495 (2002).
   PubMedGoogle Scholar
• Unutmaz D. NKT cells and HIV infection. Microbes. Infect. 5, 1041–1047 (2003).
   PubMedGoogle Scholar
• Poccia F, Gougeon ML, Agrati C et al. Innate T-cell immunity in HIV infection: the role of Vγ9Vδ2 T-lymphocytes. Curr. Mol. Med. 2(8), 769–781 (2002).
   PubMedGoogle Scholar
• Dobmeyer TS, Dobmeyer R, Wesch D, Helm EB, Hoelzer D, Kabelitz D. Reciprocal alterations of Th1/Th2 function in γδT-cell subsets of human immunodeficiency virus-1-infected patients. Br. J. Haematol. 118, 282–288 (2002).
   PubMedGoogle Scholar
• Malkovsky M, Wallace M, Fournie JJ, Fisch P, Poccia F, Gougeon ML. Alternative cytotoxic effector mechanisms in infections with immunodeficiency viruses: T-lymphocytes and natural killer cells. AIDS 14(Suppl. 3), 175–186 (2000).
   Google Scholar
• Ferlazzo G, Munz C. NK cell compartments and their activation by dentritic cells. J. Immunol. 172(3), 1333–1339 (2004).
   PubMed Web of Science ®Google Scholar
• Moretta L, Ferlazzo G, Mingari MC, Melioli G, Moretta A. Human natural killer cell function and their interactions with dentritic cells. Vaccine 21(Suppl. 2), 38–42 (2003).
   PubMedGoogle Scholar
• Valentin A, Rosati M, Patenaude DJ et al. Persistent HIV-1 infection of natural killer cells in patients receiving highly active antiretroviral therapy. Proc. Natl Acad. Sci. USA 99(10), 7015–7020 (2002).
   PubMed Web of Science ®Google Scholar
• Jacobs R, Heiken H, Schmidt RE. Mutual interference of HIV and natural killer cell-mediated response. Mol. Immunol. 42, 239–249 (2005).
   PubMedGoogle Scholar
• Bonaparte MI, Baker E. Killing of human immunodeficiency virus-infected primary T-cell blasts by autologous natural killer cells is dependent on the ability of the virus to alter the expression of major histocompatibility complex class I molecules. Blood 104(7), 2087–2094 (2004).
   PubMedGoogle Scholar
• Ward JP, Bonaparte MI, Baker E. HLA-C and HLA-E reduce antibody- dependent natural killer cell-mediated cytotoxicity of HIV-infected primary T-cell blasts. AIDS 18(13), 1769–1779 (2004).
   PubMedGoogle Scholar
• Mavilio D, Lombardo G, Benjamin J et al. Characterization of CD56-/CD16+ natural killer (NK) cells: a highly dysfunctional NK subset expended in HIV- infected viremic individuals. Proc. Natl Acad. Sci. USA 102(8), 2886–2891 (2005).
   PubMed Web of Science ®Google Scholar
• Poggi A, Carosio R, Spaggiari GM et al. NK cell activation by dentritic cells is dependent on LFA-1-mediated induction of calcium-calmodulin kinase II: inhibition by HIV-1 tat C-terminal domain. J. Immunol. 168(1), 95–101 (2002).
   PubMed Web of Science ®Google Scholar
• Tasca S, Tambussi G, Nazza S et al. Escape of monocyte-derived dentritic cells of HIV-1 infected individuals from natural killer cell-mediated lysis. AIDS 17, 2291–2298 (2003).
   PubMedGoogle Scholar
• Kedzierska K, Crowe SM. The role of monocytes and macrophages in the pathogenesis of HIV-1 infection. Curr. Med. Chem. 9(21), 1893–1903 (2002).
   PubMed Web of Science ®Google Scholar
• Chen S, Tuttle DL, Oshier JT et al. Transforming growth factor-β1 increases CXCR4 expression, stromal-derived factor-1α-stimulated signaling and human immunodeficiency virus-1 entry in human monocyte-derived macrophages. Immunology 114, 565–574 (2005).
   PubMed Web of Science ®Google Scholar
• Jayakumar P, Berger I, Autschbach F et al. Tissue-resident macrophages are productively infected ex vivo by primary X4 isolates of human immunodeficiency virus Type 1. J. Virol. 79(8), 5220–5226 (2005).
   PubMed Web of Science ®Google Scholar
• Persidsky Y, Gendelman HE. Mononuclear phagocyte immunity and neuropathogenesis of HIV-1 infection. J. Leukoc. Biol. 74, 691–701 (2003).
   PubMed Web of Science ®Google Scholar
• Verani A, Gras G, Pancino G. Macrophages and HIV-1: dangerous liaisons. Mol. Immunol. 42, 195–212 (2005).
   PubMed Web of Science ®Google Scholar
• Kedzierska K, Azzam R, Ellery P, Mak J, Jaworowski A, Crowe SM. Defective phagocytosis by human monocyte/macrophages following HIV 1 infection: underlying mechanisms and modulation by adjunctive cytokine therapy. J. Clin. Virol. 26, 247–263 (2003).
   PubMed Web of Science ®Google Scholar
• Trabattoni D, Saresella M, Biasin M et al. B7-H1 is upregulated in HIV infection and is a novel surrogate maker of disease progression. Blood 101(7), 2514–2520 (2003).
   PubMedGoogle Scholar
• Suzu S, Harada H, Matsumoto T, Okada S. HIV-1 nef interferes with M- CSF receptor signaling through Hck activation and inhibits M-CSF bioactivities. Blood 105(8), 3230–3237 (2005).
   PubMed Web of Science ®Google Scholar
• Hage CA, Kohli L, Cho S, Brutkiewicz RR, Twigg III HL, Knox KS. Human immunodeficiency virus gp 120 downregulates CD1d cell surface expression. Immunol. Lett. 98, 131–135 (2005).
   PubMedGoogle Scholar
• Jiang W, Lederman MM, Salkowitz JR, Rodriguez B, Harding CV, Sieg SF. Impaired monocyte maturation in response to CpG oligodeoxynucleotide is related to viral RNA levels in human immunodeficiency virus disease and is at least partially mediated by deficiencies in α/β interferon responsiveness and production. J. Virol. 79(7), 4109–4119 (2005).
   PubMedGoogle Scholar
• Ciborowski P, Enose Y, Mack A, Fladseth M, Gendelman HE. Diminished matrix metalloproteinase 9 secretion in human immunodeficiency virus- infected mononuclear phagocytes: modulation of innate immunity and implications for neurological disease. J. Neuroimmunol. 157(1–2), 11–16 (2004).
   PubMed Web of Science ®Google Scholar
• Sperber K, Beuria P, Singha N et al. Induction of apoptosis by HIV-1-infected monocytic cells. J. Immunol. 170, 1566–1578 (2003).
   PubMedGoogle Scholar
• Herbeuval JP, Boasso A, Grivel JC et al. TNF-related apoptosis-inducing ligand (TRAIL) in HIV-1-infected patients and its in vitro production by antigen-presenting cells. Blood 105(6), 2458–2464 (2005).
   PubMed Web of Science ®Google Scholar
• Vazquez N, Grennwell-Wild T, Marinos NJ et al. Human immunodeficiency virus Type 1-induced macrophage gene expression includes the p21 gene, a target for viral regulation. J. Virol. 79(7), 4479–4491 (2005).
   PubMed Web of Science ®Google Scholar
• Lee ES. Kalantari P, Tsutsui S et al. RON receptor tyrosine kinase, a negative regulator of inflammation, inhibits HIV-1 transcription in monocytes/macrophages and is decreased in brain tissue from patients with AIDS. J. Immunol. 173, 6864–6872 (2004).
   PubMed Web of Science ®Google Scholar
• Godstein DR. Toll-like receptors and other links between innate and acquired alloimmunoty. Curr. Opin. Immunol. 16, 538–544 (2004).
   PubMedGoogle Scholar
• Abreu MT, Arditi M. Innate immunity and toll-like receptors: clinical implications of basic science research. J. Pediatr. 144, 421–429 (2004).
   PubMed Web of Science ®Google Scholar
• Schjetne KW, Thompson KM, Nilsen N et al. Link between innate and adaptive immunity: Toll-like receptor 2 internalizes antigen for presentation to CD4+ T cells and could be an efficient Vaccine target. J. Immunol. 171, 32–36 (2003).
   PubMedGoogle Scholar
• Krug A, French AR, Barchet W et al. TLR9-dependent recognition of MCMV by IPC and DC generates co-ordinated cytokine responses that activate antiviral NK cell function. Immunity 21, 107–119 (2004).
   PubMed Web of Science ®Google Scholar
• Pasare C, Medzhitov R. Toll-dependent control mechanisms of CD4 T-cell activation. Immunity 21, 733–741 (2004).
   PubMed Web of Science ®Google Scholar
• Ahonen CL, Doxsee CL, McGurran SM et al. Combined TLR and CD40 triggering induces potent CD8+ T-cell expansion with variable dependence on Type I IFN. J. Exp. Med. 199(6), 775–784 (2004).
   PubMed Web of Science ®Google Scholar
• Komai-Koma M, Jones L, Ogg GS, Xu D, Liew FY. TLR2 is expressed on activated T-cells as a costimulatory receptor. Proc. Natl Acad. Sci. USA 101(9), 3029–3034 (2004).
   PubMed Web of Science ®Google Scholar
• Gelman AE, Zhang J, Choi Y, Turka LA. Toll-like receptor ligands promote activated CD4+ T-cell survival. J. Immunol. 172, 6065–6073 (2004).
   PubMed Web of Science ®Google Scholar
• Caramalbo I, Lopes-Carvalbo T, Ostler D, Zelenay S, Haury M, Demengeot J. Regulatory T-cells selectively express Toll-like receptors and are activated by lipopolysaccharide. J. Exp. Med. 197, 403–411 (2003).
   PubMedGoogle Scholar
• Vaidya SA, Cheng G. Toll-like receptors and innate antiviral responses. Curr. Opin. Immunol. 15, 402–407 (2003).
   PubMed Web of Science ®Google Scholar
• Boehme KW, Compton T. Innate sensing of viruses by Toll-like receptors. J. Virol. 78(15), 7867–7873 (2004).
   PubMed Web of Science ®Google Scholar
• Sato A, Iwasaki A. Induction of antiviral immunity requires Toll-like receptor signaling in both stromal and dentritic cell compartments. Proc. Natl Acad. Sci. USA 101(46), 16274–16279 (2004).
   PubMedGoogle Scholar
• Bowie AG, Haga IR. The role of Toll-like receptors in the host response to viruses. Mol. Immunol. 42, 859–867 (2005).
   PubMed Web of Science ®Google Scholar
• Equils O, Faure E, Thomas L, Bulut Y, Trushin S, Arditi M. Bacterial lipopolysaccharide activates HIV long-terminal repeat through Toll-like receptor 4. J. Immunol. 166, 2342–2347 (2001).
   PubMedGoogle Scholar
• Bafica A, Scanga CA, Schito ML, Hieny S, Sher A. In vivo induction of integrated HIV-1 expression by mycobacteria is critically dependent on Toll-like receptor 2. J. Immunol. 171, 1123–1127 (2003).
   PubMedGoogle Scholar
• Equils O, Schito ML, Karahashi H et al. Toll-like receptor 2 (TLR2) and TLR9 signaling results in HIV-long-terminal repeat trans-activation and HIV replication in HIV-1 transgenic mouse spleen cells: Implications of simultaneous activation of TLRs on HIV replication. J. Immunol. 170, 5159–5164 (2003).
   PubMedGoogle Scholar
• Bafica A, Scanga CA, Schito M, Chaussabel D, Sher A. Influence of coinfecting pathogens on HIV expression: Evidence for a role of Toll-like receptors. J. Immunol. 172, 7229–7234 (2004).
   PubMed Web of Science ®Google Scholar
• Scheller C, Ullrich A, McPherson K et al. CpG oligodeoxynucleotides activate HIV replication in latently infected human T-cells. J. Biol. Chem. 279(21), 21897–21902 (2004).
   PubMed Web of Science ®Google Scholar
• Sundstrom JB, Little DM, Villinger F, Ellis JE, Ansari AA. Signaling through Toll-like receptors triggers HIV-1 replication in latently infected mast cells. J. Immunol. 172, 4391–4401 (2004).
   PubMed Web of Science ®Google Scholar
• Heggelund L, Muller F, Lien E et al. Increased expression of Toll-like receptor 2 on monocytes in HIV infection: possible roles in inflammation and viral replication. Clin. Infect. Dis. 39(2), 264–269 (2004).
   PubMed Web of Science ®Google Scholar
• Heggelund L, Flo T, Berg K et al. Soluble toll-like receptor 2 in HIV infection: association with disease progression. AIDS 18(18), 2437–2439 (2004).
   PubMed Web of Science ®Google Scholar
• Agrawal S, Martin RR. Was induction of HIV-1 through TLR9? J. Immunol. 171(4), 1621–1643 (2003).
   PubMed Web of Science ®Google Scholar
• Lore K, Larsson M. The role of dentritic cells in the pathogenesis of HIV-1 infection. APMIS 111(7–8), 776–788 (2003).
   PubMedGoogle Scholar
• Siegal FP, Spear GT. Innate immunity and HIV. AIDS 15(Suppl. 5), 127–137 (2001).
   Google Scholar
• Turville S, Wilkinson J, Cameron P, Dable J, Cunningham AL. The role of dentritic cell C-type lectin receptors in HIV pathogenesis. J. Leukoc. Biol. 74, 710–718 (2003).
   PubMed Web of Science ®Google Scholar
• Kasper MR, Roeth JF, Williams M, Filzen TM, Fleis RI, Collins KL. HIV-1 nef disrupts antigen presentation early in the secretory pathway. J. Biol. Chem. 280(13), 12840–12848 (2005).
   PubMedGoogle Scholar
• Izmailova E, Bertley FM, Huang Q et al. HIV-1 tat reprograms immature dentritic cells to express chemoattractants for activated T-cells and macrophages. Nature Med. 9(2), 191–197 (2003).
   PubMedGoogle Scholar
• Majumder B, Janket ML, Schafer EA et al. Human immunodeficiency virus Type 1 vpr impairs dentritic cell maturation and T-cell activation: implications for viral immune escape. J. Virol. 79(13), 7990–8003 (2005).
   PubMedGoogle Scholar
• Granelli-Piperno A, Golebiowska A, Trumpfheller C, Siegal FP, Steinman RM. HIV-1-infected monocyte-derived dentritic cells do not undergo maturation but can elicit IL-10 production and T-cell regulation. Proc. Natl Acad. Sci. USA 101(20), 7669–7674 (2004).
   PubMed Web of Science ®Google Scholar
• Smed-Sorensen A, Lore K, Walther-Jallow L, Andersson J, Spetz AL. HIV-1 infected dentritic cells upregulate cell surface markers but fail to produce IL-12 p70 in response to CD40 ligand stimulation. Blood 104(9), 2810–2817 (2004).
   PubMed Web of Science ®Google Scholar
• Anthony DD, Yonkers NL, Post AB et al. Selective impairments in dentritic cell-associated function distinguish hepatitis C virus and HIV infection. J. Immunol. 172, 4907–4916 (2004).
   PubMed Web of Science ®Google Scholar
• Almeida M, Cordero M, Almeida J, Orfao A. Different subsets of peripheral blood dentritic cells show distinct phenotypic and functional abnormalities in HIV-1 infection. AIDS 19(3), 261–271 (2005).
   PubMedGoogle Scholar
• Donaghy H, Gazzard B, Gotch F, Patterson S. Dysfunction and infection of freshly isolated blood myeloid and plasmacytoid dentritic cells in patients infected with HIV-1. Blood 101(11), 4505–4511 (2003).
   PubMedGoogle Scholar
• Donaghy H, Pozniak A, Gazzard B et al. Loss of blood CD11c+ myeloid and CD11c- plasmacytoid dentritic cells in patients with HIV-1 infection correlates with HIV-1 RNA virus load. Blood 98(8), 2574–2576 (2001).
   PubMed Web of Science ®Google Scholar
• Pacanowski J, Kahi S, Baillet M et al. Reduced blood CD123+ (lymphoid) and CD11c+ (myeloid) dentritic cell numbers in primary HIV-1 infection. Blood 98(10), 3016–3021 (2001).
   PubMed Web of Science ®Google Scholar
• Donaghy H, Stebbing J, Patterson S. Antigen presentation and the role of dentritic cells in HIV. Curr. Opin. Infect. Dis. 17(1), 1–6 (2004).
   PubMed Web of Science ®Google Scholar
• Willemot P, Klein MB. Prevention of HIV-associated opportunistic infections and disease in the age of highly active antiretroviral therapy. Expert Rev. Anti-infect. Ther. 2(4), 521–532 (2004).
   PubMedGoogle Scholar
• Turpin JA. The next generation of HIV/AIDS drugs: novel and developmental antiHIV drugs and targets. Expert Rev. Anti-infect. Ther. 1(1), 97–128 (2003).
   PubMedGoogle Scholar
• Steinhart CR. Recent advances in the treatment of HIV/AIDS. Expert Rev. Anti-infect. Ther. 2(2), 197–211 (2004).
   PubMedGoogle Scholar
• Gandi RT, Walker BD. Promises and pitfalls in the reconstitution of immunity in patients who have HIV-1 infection. Curr. Opin. Immunol. 14, 487–494 (2002).
   PubMedGoogle Scholar
• Hatzakis A, Touloumi G, Karanicolas R et al. Effect of recent thymic emigrants on progression of HIV-1 disease. Lancet 355, 599–604 (2000).
   PubMed Web of Science ®Google Scholar
• Boritz E, Palmer BE, Livingston B, Sette A, Wilson CC. Diverse repertoire of HIV-1 p24-specific, IFN producing CD4+ T-cell clones following immune reconstruction of highly active antiretroviral therapy. J. Immunol. 170, 1106–1116 (2003).
   PubMedGoogle Scholar
• Leibowitz MR, Mitsuyasu RT. Immune reconstitution strategies in HIV. Curr. Infect. Dis. Rep. 3, 302–308 (2001).
   PubMedGoogle Scholar
• Harari A, Petitpierre S, Vallelian F, Pantaleo G. Skewed representation of functionally distinct populations of virus-specific CD4 T-cells in HIV-1-infected subjects with progressive disease: changes after antiretroviral therapy. Blood 103(3), 966–972 (2004).
   PubMedGoogle Scholar
• Tsunemi S, Iwasaki T, Imado T et al. Relationship of CD4+CD25+ regulatory T-cells to immune status in HIV-infected patients. AIDS 19(9), 879–886 (2005).
   PubMed Web of Science ®Google Scholar
• Badley AD, Pilon AA, Landay A, Lynch DH. Mechanisms of HIV- associated lymphocyte apoptosis. Blood 96(9), 2951–2964 (2000).
   PubMed Web of Science ®Google Scholar
• Amendola A, Poccia F, Martini F et al. Decreased CD95 expression on naive T-cells from HIV-infected persons undergoing highly active antiretroviral therapy (HAART) and the influence of IL-2 low dose administration. Clin. Exp. Immunol. 120, 324–332 (2000).
   PubMedGoogle Scholar
• Munoz-Calleja C, Costantini A, Silvestri G et al. Highly active antiretroviral therapy induces specific changes in effector and central memory T-cell sub-populations. AIDS 15(14), 1887–1890 (2001).
   PubMedGoogle Scholar
• Weber K, Meyer D, Grosse V, Stoll M, Schmidt RE, Heiken H. Reconstitution of NK cell activity in HIV-1 infected individuals receiving antiretroviral therapy. Immunobiology 202(2), 172–178 (2000).
   PubMedGoogle Scholar
• Wiercinska-Drapolo A, Jaroszewicz J, Flisiak R, Prokopowicz D. Plasma interleukin-18 is associated with viral load and disease progression in HIV-1 infected patients. Microbes. Infect. 6, 1273–1277 (2004).
   PubMedGoogle Scholar
• Darcissac ECA, Vidal V, De La Tribonniere X, Mouton Y, Bahr GM. Variations in serum IL-7 and 90K/Mac-2 binding protein (Mac-2 BP) levels analysed in cohorts of HIV-1 patients and correlated with clinical changes following antiretroviral therapy. Clin. Exp. Immunol. 126, 287–294 (2001).
   PubMedGoogle Scholar
• Kamga I, Kahi S, Develioglu L et al. Type I interferon production is profoundly and transiently impaired in primary HIV-1 infection. J. Infect. Dis. 192(2), 303–310 (2005).
   PubMed Web of Science ®Google Scholar
• Chehimi J, Campbell DE, Azzoni L et al. Persistent decreases in blood plasmacytoid dentritic cell number and function despite effective highly active antiretroviral therapy and increased blood myeloid dentritic cells in HIV-infected individuals. J. Immunol. 168, 4796–4801 (2002).
   PubMedGoogle Scholar
• Barron MA, Blyveis N, Palmer BE, MaWhinney S, Wilson CC. Influence of plasma viremia on defects in number and immunophenotype of blood dentritic cell subsets in human immunodeficiency virus 1-infected individuals. J. Infect. Dis. 187, 26–37 (2003).
   PubMedGoogle Scholar
• Mavilio D, Benjamin J, Daucher M et al. Natural killer cells in HIV-1 infection: Dichotomous effects of viremia on inhibitory and activating receptors and thei functional correlates. Proc. Natl Acad. Sci. USA 100(25), 15011–15016 (2003).
   PubMed Web of Science ®Google Scholar
• Azzoni L, Papasavvas E, Chehimi J et al. Sustained impairment of IFN- gamma secretion in suppressed HIV-infected patients despite mature NK cell recovery: evidence for a defective reconstitution of innate immunity. J. Immunol. 168(11), 5764–5770 (2002).
   PubMedGoogle Scholar
• Carbonneil C, Donkova-Petrini V, Aouba A, Weiss L. Defective dentritic cell function in HIV-infected patients receiving effective highly active antiretroviral therapy: Neutralization of IL-10 production and depletion of CD4+CD25+ T-cells restore high levels of HIV-specific CD4+ T-cell responses induced by dentritic cells generated in the presence of IFN-α. J. Immunol. 172, 7832–7840 (2004).
   PubMedGoogle Scholar
• Pett SL. Kelleher AD. Cytokine therapies in HIV-1 infection: present and future. Expert Rev. Anti-infect. Ther. 1(1), 83–96 (2003).
   PubMedGoogle Scholar
• Sereti I, Anthony KB, Martinez-Wilson H et al. IL-2-induced CD4+ T-cell expansion in HIV-infected patients is associated with long-term decreases in T-cell proliferation. Blood 104(3), 775–780 (2004).
   PubMedGoogle Scholar
• Sereti I, Imamichi H, Natarajan V et al. In vivo expansion of CD4+CD45RO-CD25+ T-cells expressing foxP3 in IL-2-treated HIV-infected patients. J. Clin. Invest. 115(7), 1839–1847 (2005).
   PubMed Web of Science ®Google Scholar
• Mueller YM, Petrovas C, Bojczuk PM et al. Interleukin-15 increases effector memory CD8+ T-cells and NK cells in simian immunodeficiency virus-infected macaques. J. Virol. 79(8), 4877–4885 (2005).
   PubMed Web of Science ®Google Scholar
• Levine BL, Bernstein WB, Aronson NE et al. Adoptive transfer of costimulated CD4+ T-cells induces expansion of peripheral T-cells and decreases CCR5 expression in HIV infection. Nature Med. 8(1), 47–53 (2002).
   PubMed Web of Science ®Google Scholar
• Bernstein WB, Cox JH, Aronson NE et al. Immune reconstitution following autologous transfers of CD3/CD28 stimulated CD4+ T-cells to HIV-infected persons. Clin. Immunol. 111(3), 262–274 (2004).
   PubMedGoogle Scholar
• Garber DA, Silvestri G, Barry AP et al. Blockade of T-cell costimulation reveals interrelated actions of CD4+ and CD8+ T-cells in control of SIV replication. J. Clin. Invest. 113(6), 836–845 (2004).
   PubMedGoogle Scholar
• Stiehm ER, Fletcher CV, Mofenson LM et al. Use of human immunodeficiency virus (HIV) human hyperimmune immunoglobulin in HIV Type 1-infected children (Pediatric AIDS clinical trials group protocol 273). J. Infect. Dis. 181, 548–554 (2000).
   PubMed Web of Science ®Google Scholar
• McComsey GA, Whalen CC, Mawhorter SD et al. Placebo-controlled trial of prednisone in advanced HIV-1 infection. AIDS 15(3), 321–327 (2001).
   PubMed Web of Science ®Google Scholar
• Haslett PA, Klausner JD, Makonkawkeyoon S et al. Thalidomide stimulates T-cell responses and interleukin-12 production in HIV-infected patients. AIDS Res. Hum. Retroviruses. 15(13), 1169–1179 (1999).
   PubMed Web of Science ®Google Scholar
• Franks ME, Macpherson GR, Figg WD. Thalidomide. Lancet 363(9423), 1802–1811 (2004).
   PubMed Web of Science ®Google Scholar
• Kurktschiev D, Temelkova-Kurktschiev T, Horn K, Schentke KU. Successful immunomodulating in AIDS patients with ursodeoxycholic acid – a pilot study. Clin. Exp. Immunol. 115, 144–146 (1999).
   PubMedGoogle Scholar
• Chapuis AG, Rizzardi P, D’Agostino C et al. Effects of mycophenoloc acid on human immunodeficiency virus infection in vitro and in vivo. Nature Med. 6(7), 762–768 (2000).
   PubMedGoogle Scholar
• Sankatsing SUC, Jurriaans S, van Swieten P et al. Highly active antiretroviral therapy with or without mycophenolate mofetil in treatment-naive HIV-1 patients. AIDS 18(14), 1925–1931 (2004).
   PubMed Web of Science ®Google Scholar
• Gori A, Trabattoni D, Bandera A et al. Immunomodulation induced by tucaresol in HIV infection: results of a 16 week pilot Phase I/II trial. Antivir. Ther. 9(4), 603–614 (2004).
   PubMed Web of Science ®Google Scholar
• Wang W. Technology evaluation: reticulose, advanced research. Curr. Opin. Mol. Ther. 5(2), 186–191 (2003).
   PubMedGoogle Scholar
• Breitkreutz R, Pittack N, Nebe CT et al. Improvement of immune functions in HIV infection by sulfur supplementation: two randomized trials. J. Mol. Med. 78, 55–62 (2000).
   PubMed Web of Science ®Google Scholar
• Goldstein G, Conant MA, Beall G et al. Safety and efficacy of thymopentin in zidovudine (AZT)-treated asymptomatic HIV-infected subjects with 200- 500 CD4 cells mm3: a double-blind placebo-controlled trial. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 18(3), 279–288 (1995).
   Google Scholar
• Chadwick D, Pido-Lopez J, Pires A et al. A pilot study of the safety and efficacy of thymosin α-1 in augmenting immune reconstitution in HIV- infected patients with low CD4 counts taking highly active antiretroviral therapy. Clin. Exp. Immunol. 134(3), 477–481 (2003).
   PubMed Web of Science ®Google Scholar
• Portales P, Reynes J, Rouzier-Panis R, Baillat V, Clot J, Corbeau P. Perforin expression in T-cells and virological response to PEG-interferon α2β in HIV-1 infection. AIDS 17, 505–511 (2003).
   PubMedGoogle Scholar
• Emilie D, Burgard M, Lascoux-Combe C et al. Early control of HIV replication in primary HIV-1 infection treated with antiretroviral drugs and pegylated IFN alpha: results from the primoferon A (ANRS 086) study. AIDS 15(11), 1435–1437 (2001).
   PubMed Web of Science ®Google Scholar
• Angel JB, Jacobson MA, Skolnik PR et al. A multicenter, randomized, double-blind, placebo-controlled trial of recombinant human interleukin-10 in HIV-infected subjects. AIDS 14, 2503–2508 (2000).
   PubMed Web of Science ®Google Scholar
• Jacobson MA, Spritzler J, Landay A et al. A Phase I, placebo-controlled trial of multi-dose recombinant human interleukin-12 in patients with HIV infection. AIDS 16(8), 1147–1154 (2002).
   PubMedGoogle Scholar
• Aladdin H, Ullum H, Dam Nielson S et al. Granulocyte colony-stimulating factor increases CD4+ T-cell counts of human immunodeficiency virus- infected patients receiving stable, highly active antiretroviral therapy: results from a randomized, placebo-controlled trial. J. Infect. Dis. 181(3), 1148–1152 (2000).
   PubMedGoogle Scholar
• Imani N, Gotch F. Prospects for immune reconstitution in HIV-1 infection. Clin. Exp. Immunol. 127, 402–411 (2002).
   PubMedGoogle Scholar
• Nguyen BY, Clerici M, Venzon DJ et al. Pilot study of the immunologic effects of recombinant human growth hormone and recombinant insulin-like growth factor in HIV-infected patients. AIDS 12(8), 895–904 (1998).
   PubMed Web of Science ®Google Scholar
• Moss RB, Brandt C, Giermakowska WK et al. HIV-specific immunity during structured antiviral drug treatment interruption. Vaccine 21, 1066–1071 (2003).
   PubMed Web of Science ®Google Scholar
• Ananworanich J, Hirshel B. Interrupting highly active antiretroviral therapy in patients with HIV. Expert Rev. Anti-infect. Ther. 3(1), 51–60 (2005).
   PubMedGoogle Scholar
• Berzofsky JA, Ahlers JD, Janik J et al. Progress on new vaccine strategies against chronic viral infections. J. Clin. Invest. 114(4), 450–462 (2004).
   PubMed Web of Science ®Google Scholar
• Autran B, Costagliola D, Murphy R, Katlama C. Evaluating therapeutic vaccines in patients infected with HIV. Expert Rev.Vaccines. 3(4 Suppl.). 169–177 (2004).
   PubMedGoogle Scholar
• Wahren B, Liu M. Therapeutic vaccination against HIV. Expert Rev. Vaccines 3(4 Suppl.). 1–10 (2004).
   PubMedGoogle Scholar
• Kran AM, Sorensen B, Nyhus J et al. HLA-and dose-dependent immunogenicity of a peptide-based HIV-1 immunotherapy candidate (Vacc- 4x). AIDS 18(14), 1875–1883 (2004).
   PubMed Web of Science ®Google Scholar
• Walsh SR, Bhardwaj N, Gandhil RT. Dentritic cells and the promise of therapeutic vaccines for human immunodeficiency virus (HIV)-1. Curr. HIV Res. 1(2), 205–216 (2003).
   PubMedGoogle Scholar
• Garcia F, Lejeune M, Climent N et al. Therapeutic immunization with dentritic cells loaded with heat-inactivated autologous HIV-1 in patients with chronic HIV-1 infection. J. Infect.Dis. 191(10), 1680–1685 (2005).
   PubMed Web of Science ®Google Scholar
• Fernandez-Cruz E, Navarro J, Rodriguez-Sainz C et al. The potential role of the HIV-1 immunogen (Remune) as a therapeutic Vaccine in treatment of HIV infection. Expert Rev.Vaccines 2, 739–752 (2003).
   Google Scholar
• Moss RB, Brandt C, Giermakowska W et al. HIV-specific immunity during structured antiviral drug treatment interruption. Vaccine 21, 1066–1071 (2003).
   PubMed Web of Science ®Google Scholar
• Coffey MJ, Phare SM, George S, Peters-Golden M, Kazanjian PH. Granulocyte colony-stimulating factor administration to HIV-infected subjects augments reduced leukotriene synthesis and anticryptococcal activity in neutrophils. J. Clin. Invest. 102(4), 663–670 (1998).
   PubMedGoogle Scholar
• Kuritzkes DR, Parenti D, Ward DJ et al. Filgrastim prevents severe neutropenia and reduces infective morbidity in patients with advanced HIV infection: results of a randomized, multicenter, controlled trial. AIDS 12, 65–74 (1998).
   PubMedGoogle Scholar
• Brites C, Gilbert MJ, Pedral-Sampaio D et al. A randomized, placebo-controlled trial of granulocyte-macrophage colony-stimulating factor and nucleoside analogue therapy in AIDS. J. Infect. Dis. 182, 1531–1535 (2000).
   PubMed Web of Science ®Google Scholar
• Angel JB, High K, Rhame F et al. Phase III study of granulocyte- macrophage colony-stimulating factor in advanced HIV disease: effect on infections, CD4 cell counts and HIV suppression. AIDS 14, 387–395 (2000).
   PubMed Web of Science ®Google Scholar
• Fagard C, Le Braz M, Gunthard H et al. A controlled trial of granulocyte macrophage-colony stimulating factor during interruption of HAART. AIDS 17, 1487–1492 (2003).
   PubMed Web of Science ®Google Scholar
• Kedzierska K, Paukovics G, Handley A et al. Interferon-γ therapy activates human monocytes for enhanced phagocytosis of mycobacterium avium complex in HIV infected individuals. HIV Clin.Trials 5(2), 80–85 (2004).
   PubMed Web of Science ®Google Scholar
• Gieseler RK, Marquitan G, Scolaro MJ, Cohen MD. Lessons from history: dysfunctional APCs, inherent dangers of STI and an important goal, as yet unmet. Trends Immunol. 24(1), 11 (2003).
   PubMedGoogle Scholar
• Lu W, Achour A, Arlie M, Cao L, Andrieu JM. Enhanced dentritic cell-driven proliferation and antiHIV active CD8+ T-cell by a new phenothiazine derivative, aminoperazine. J. Immunol. 167(5), 2929–2935 (2001).
   PubMedGoogle Scholar
• De Becker G, Moulin V, Pajak B et al. The adjuvant monophosphoryl lipid A increases the function of antigen-presenting cells. Int. Immunol. 12(6), 807– 815 (2000).
   PubMed Web of Science ®Google Scholar
• Bahr GM. Non-specific immunotherapy of HIV-1 infection: potential use of the synthetic immunomodulator murabutide. J. Antimicrob. Chemother. 51, 5–8 (2003).
   PubMedGoogle Scholar
• Bahr GM, Darcissac E, Bevec D, Dukor P, Chedid A. Immunopharmacological activities and clinical development of muramyl peptides with particular emphasis on murabutide. Int. J. Immunopharmacol. 14(2), 117–131 (1995).
   Google Scholar
• Vidal VF, Casteran N, Riendeau CJ et al. Macrophage stimulation with murabutide, an HIV-suppressive muramyl peptide derivative, selectively activate extracellular signal-regulated kinases 1 and 2, C/EBPβ and STAT1: role of CD14 and Toll-like receptors 2 and 4. Eur. J. Immunol. 31, 1962–1971 (2001).
   Google Scholar
• Vidal V, Dewulf J, Bahr GM. Enhanced maturation and functional capacity of monocyte-derived immature dentritic cells by the synthetic immunomodulator murabutide. Immunology 103, 479–487 (2001).
   PubMedGoogle Scholar
• Darcissac EA, Truong MJ, Dewulf J et al. The synthetic immunomodulator murabutide controls human immunodeficiency virus Type 1 replication at multiple levels in macrophages and dentritic cells. J. Virol. 74(17), 7794–7802 (2000).
   PubMed Web of Science ®Google Scholar
• Bahr GM, Darcissac EA, Casteran N et al. Selective regulation of human immunodeficiency virus-infected CD4+ lymphocytes by a synthetic immunomodulator leads to potent virus suppression in vitro and in hu-PBL- SCID mice. J. Virol. 75(15), 6941–6952 (2001).
   PubMedGoogle Scholar
• Goasduff T, Darcissac EA, Vidal V, Capron A. Bahr GM. The transcriptional response of human macrophages to murabutide reflects a spectrum of biological effects for the synthetic immunomodulator. Clin. Exp. Immunol. 128, 474–482 (2002).
   PubMedGoogle Scholar
• Cocude C. Truong MJ, Billaut-Mulot O et al. A novel cellular RNA helicase, RH116, differentially regulates cell growth, programmed cell death and human immunodeficiency virus Type 1 replication. J. Gen. Virol. 84, 3215–3225 (2003).
   PubMed Web of Science ®Google Scholar
• Truong MJ, Delsart V, Bahr GM. Differentially expressed genes in HIV-1- infected macrophages following treatment with the virus-suppressive immunomodulator murabutide. Virus Res. 99, 25–33 (2004).
   PubMedGoogle Scholar
• Amiel C, De La Tribonniere X, Vidal V, Darcissac E, Mouton Y, Bahr GM. Clinical tolerance and immunologic effects after single or repeated administrations of the synthetic immunomodulator murabutide in HIV-1-infected patients. J. Acquir. Immune defic. Synd. 30, 294–305 (2002).
   PubMedGoogle Scholar
• De La Tribonniere X, Mouton Y, Vidal V et al. A Phase I study of a six-week cycle of immunotherapy with murabutide in HIV-1 patients naive to antiretrovirals. Med. Sci. Monit. 9(6), 43–50 (2003).
   Google Scholar
• Bahr GM, De La Tribonniere X, Darcissac E et al. Clinical and immunological effects of a 6 week immunotherapy cycle with murabutide in HIV-1 patients with unsuccessful long-term antiretroviral treatment. J. Antimicrob. Chemother. 51, 1377–1388 (2003).
   PubMedGoogle Scholar
• Gougeon ML, Malkovsky M, Casetti R, Agrati C, Poccia F. Innate T-cell immunity to HIV-infection: immunotherapy with phosphocarbohydrates, a novel strategy of immune intervention. Vaccine 20, 1938–1941 (2002).
   PubMedGoogle Scholar
• Kunzmann V, Bauer E, Feurle J et al. Stimulation of T-cells by aminobiphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood 96, 384–392 (2000).
   PubMed Web of Science ®Google Scholar
• Gupta N, Arthos J, Khazanie P et al. Targeted lysis of HIV-infected cells by natural killer cells armed and triggered by a recombinant immunoglobulin fusion protein: implications for immunotherapy. Virology 332(2), 491–497 (2005).
   PubMedGoogle Scholar
• Portales P, Reynes J, Pinet V et al. Interferon-α restores HIV-induced alteration of natural killer cell perforin expression in vivo. AIDS 17, 495–504 (2003).
   PubMedGoogle Scholar
• Goldstein D, Hertzog P, Tomkinson E et al. Administration of imiquimod, an interferon inducer, in asymptomatic human immunodeficiency virus-infected persons to determine safety and biologic response modification. J. Infect. Dis. 178(3), 858–861 (1998).
   PubMed Web of Science ®Google Scholar
• Jansen CA, De Cuyper IM, Steingrover R et al. Analysis of the effect of highly acive antiretroviral therapy during acute HIV-1 infection on HIV-specific CD4 T cell function. AIDS 19(11), 1145–1154 (2005).
   PubMedGoogle Scholar
• Sankaran S, Guadalupe M, Reay E et al. Gut mucosal T-cell responses and gene expression correlate with protection against disease in long-term HIV-1-infected nonprogressors. Proc. Natl Acad. Sci. USA 102(28), 9860–9865 (2005).
   PubMedGoogle Scholar